| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | ||
| Market Cap | 53.27 Cr. | |
| Enterprise Value(EV) | 115.66 Cr. | 2023-03 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | 1.66 | Trailing Twelve Months Ending 2023-06 |
| Price-Earning Ratio (PE) | 21.52 | Trailing Twelve Months Ending 2023-06 |
| Industry PE | 37.95 | Trailing Twelve Months Ending 2023-06 |
| Book Value / Share | 34.90 | Trailing Twelve Months Ending 2023-06 |
| Price to Book Value | 1.02 | Calculated using Price: 35.74 |
| Dividend Yield | 0.00 | Period Ending 2022-03 |
| No. of Shares Subscribed | 1.49 Cr. | 14,903,520 Shares |
| FaceValue | 10 | |
| About Vivo Bio Tech Ltd. | ||
| Vivo Bio Tech was incorporated on February 12, 1987 as Golden Growth Fund, Hyderabad-based Vivo Bio Tech (VBTL) is a contract research company engaged in biotechnology and pharma drug discovery activities. The company was converted into a public limited company from Jun. 19, 1992. VBTL provides services ranging from insilico design, wet lab contract research, preclinical research and clinical studies spanning the entire drug discovery value chain. | ||
| 1 Day |
|
-1.73% |
| 1 Week |
|
+5.72% |
| 1 Month |
|
+24.41% |
| 3 Month |
|
+20.36% |
| 6 Month |
|
+59.85% |
| 1 Year |
|
-6.97% |
| 2 Year |
|
-53.61% |
| 5 Year |
|
-40.88% |
| 10 Year |
|
+156.35% |
| 9 years | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | |
| Return on Equity (%) | 3.52 | 5.25 | 9.48 | 22.17 | 21.01 | 10.21 | 14.85 | 15.36 | 5.06 | |
| Return on Capital Employed (%) | 7.95 | 4.72 | 5.96 | 12.39 | 15.18 | 9.58 | 13.85 | 18.81 | 9.32 | |
| Return on Assets (%) | 0.75 | 1.14 | 2.09 | 5.17 | 5.64 | 3.92 | 7.58 | 8.02 | 2.18 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03* Rs. Cr. |
| Shh. Funds | 9 | 9 | 10 | 13 | 19 | 27 | 33 | 43 | 47 | 52 | |
| Non Curr. Liab. | 5 | 4 | 15 | 22 | 15 | 9 | 9 | 15 | 52 | 46 | |
| Curr. Liab. | 26 | 28 | 20 | 17 | 25 | 19 | 21 | 22 | 23 | 25 | |
| Minority Int. | |||||||||||
| Equity & Liab. | 40 | 41 | 46 | 51 | 60 | 55 | 62 | 80 | 122 | 123 | |
| Non Curr. Assets | 21 | 20 | 24 | 32 | 32 | 30 | 35 | 52 | 96 | 91 | |
| Curr. Assets | 19 | 22 | 22 | 20 | 28 | 25 | 27 | 27 | 26 | 32 | |
| Misc. Exp. not W/O | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Total Assets | 40 | 41 | 46 | 51 | 60 | 55 | 62 | 80 | 122 | 123 |
| Particulars | 10 years | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-06 Rs. Cr. TTM |
| Net Sales | 16 | 18 | 29 | 34 | 47 | 56 | 55 | 52 | 51 | 53 | |
| Other Income | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Total Income | 17 | 19 | 29 | 35 | 47 | 56 | 55 | 52 | 51 | 53 | |
| Total Expenditure | -14 | -15 | -25 | -27 | -36 | -46 | -43 | -34 | -35 | -31 | |
| PBIDT | 3 | 4 | 5 | 8 | 11 | 10 | 13 | 18 | 16 | 21 | |
| Interest | 0 | -1 | 0 | -1 | -2 | -3 | -3 | -4 | -4 | -8 | |
| Depreciation | -2 | -3 | -3 | -4 | -5 | -5 | -5 | -6 | -7 | -9 | |
| Taxation | 0 | 0 | 0 | 0 | -1 | 0 | 0 | -3 | -2 | -2 | |
| Exceptional Items | |||||||||||
| PAT | 0 | 0 | 1 | 3 | 3 | 2 | 4 | 6 | 2 | 2 | |
| Minority Interest | |||||||||||
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | 0 | 0 | 1 | 3 | 3 | 2 | 4 | 6 | 2 | 2 | |
| Adjusted EPS | 0 | 0 | 1 | 3 | 3 | 2 | 3 | 4 | 2 | 2 |
| Particulars | 10 years | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. |
| Cash Fr. Operatn. | 2 | 3 | 2 | 9 | -6 | 11 | -1 | 9 | 14 | 14 | |
| Cash Fr. Inv. | 25 | -1 | -2 | -7 | -12 | -5 | -4 | -10 | -23 | -51 | |
| Cash Fr. Finan. | -19 | 0 | -1 | 0 | 7 | -3 | 1 | 2 | 9 | 38 | |
| Net Change | 8 | 1 | -1 | 1 | -11 | 3 | -4 | 0 | 0 | 1 | |
| Cash & Cash Eqvt | 10 | 11 | 11 | 12 | 1 | 4 | 1 | 1 | 1 | 2 |
|
Thu, 21 Sep 2023
Board Meeting Outcome for Business Items Transacted/Approved On September 21 2023 Vivo Bio Tech Limited has informed the exchange that with reference to the Companys letter dated September 17 2023 the Board of Directors of the Company at their meeting held today i.e. Thursday September 21 2023 inter-alia transacted the following business:1. Approval for engagement/appointment of Consultants or Intermediaries for the proposed issuance of Equity Shares/Warrants by way of a Preferential Allotment in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 and the Companies Act 2013 as amended subject to such regulatory/ statutory approvals as may be required. |
|
Sun, 17 Sep 2023
Board Meeting Intimation for Proposal For Preferential Issuance Of Equity Shares/Warrants VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2023 inter alia to consider and approve VIVO BIO TECH LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/09/2023 inter alia to consider and approve 1. Proposal for issuance of equity shares/warrants by way of a preferential allotment in accordance with the provisions of the SEBI (Issue of Capital and Disclosure Requirements) Regulations 2018 and the Companies Act 2013 as amended subject to such regulatory/ statutory approvals as may be required.2. Convening of an Extra-Ordinary General Meeting or Postal Ballot process to seek approval of the shareholders in respect of the aforesaid proposal of preferential allotment as required. |
|
Sat, 09 Sep 2023
Announcement under Regulation 30 (LODR)-Newspaper Publication Vivo Bio Tech Limited has submitted with the exchange the Newspaper Advertisement for Notice of 36th Annual General Meeting of the Company |
| Thu, 21 Sep 2023 |
Close Within 52 Week High Zone
|
Close Above Last Week High
|
Close Above Last Month High
|
High Increase in 1 Month
|
High Increase in 3 Months
|
Equities
M.F.
Sectors
StockEdge Social